Patent: 10,029,011
✉ Email this page to a colleague
Summary for Patent: 10,029,011
Title: | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine |
Abstract: | A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof, an insulin or/and a pharmacologically tolerable salt thereof, and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin where appropriate. |
Inventor(s): | Hagendorf; Annika (Frankfurt am Main, DE), Hauck; Gerrit (Frankfurt am Main, DE), Mueller; Werner (Frankfurt am Main, DE), Schoettle; Isabell (Frankfurt am Main, DE), Siefke-Henzler; Verena (Frankfurt am Main, DE), Tertsch; Katrin (Frankfurt am Main, DE) |
Assignee: | SANOFI-AVENTIS DEUTSCHLAND GMBH (Frankfurt am Main, DE) |
Application Number: | 13/509,542 |
Patent Claims: | see list of patent claims |
Details for Patent 10,029,011
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Sanofi-aventis U.s. Llc | LANTUS | insulin glargine | Injection | 021081 | 04/20/2000 | ⤷ Try a Trial | 2029-11-13 |
Sanofi-aventis U.s. Llc | LANTUS | insulin glargine | Injection | 021081 | 04/25/2007 | ⤷ Try a Trial | 2029-11-13 |
Eli Lilly And Company | BASAGLAR | insulin glargine | Injection | 205692 | 12/16/2015 | ⤷ Try a Trial | 2029-11-13 |
Eli Lilly And Company | BASAGLAR | insulin glargine | Injection | 205692 | 11/15/2019 | ⤷ Try a Trial | 2029-11-13 |
Mylan Pharmaceuticals Inc. | SEMGLEE | insulin glargine | Injection | 210605 | 06/11/2020 | ⤷ Try a Trial | 2029-11-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |